VUNO Inc., South Korean artificial intelligence (AI) developer is showcasing its solutions at the European Con...
Bridge Biotherapeutics Inc., a clinical-stage biotech company headquartered in Seongnam, Republic of Korea and BaseLaunc...
South Korea based companies Samsung Biologics and ImmuneOncia Therapeutics held a signing ceremony for a contract to dev...
AVATAMED and CBmed, together with AIMEDBIO and Shimadzu Corporation, are collaborating in a Precision Cancer Project, le...
South Korea based Samsung Biologics has further expanded its partnership with STCube through an additional development a...
South Korean startup WellsCare, a member company of the Born2Global Centre (B2G), will be expanding its presence in the&...
Korea's Daewoong Pharmaceutical’s original botulinum toxin product Nabota is stepping up to expand its influence a...
Oculight announced the launching of OCU L&C, a fully-owned U.S. subsidiary of Oculight, in 2019 as the platform for ...
Janssen Korea Ltd. and Johnson & Johnson Innovation LLC have announced the launch of the Seoul Innovation QuickFire ...
South Korea based PharmAbcine, a biotech company focusing on the development of antibody therapeutics, announced that it...
Nine Technology, a Korean correct posture device manufacturing company, has recently been promoting hihip, pelvic care p...
Japanese firm Eisai Co., Ltd. has announced that Eisai Korea Inc., Eisai’s subsidiary in South Korea, has received...
South Korea based medical artificial intelligence (AI) solution development company VUNO Inc. and a member com...
A Korean molecular diagnostic company, Gencurix, Inc., has announced that they have received U.S. Food and Drug Administ...
The leading Asia-Pacific biotech specialist CRO Novotech has partnered with South Korea’s world-class 1,...
South Korea based Genexine has announced that it is the first domestic pharmaceutical company to have been approved for ...
HONG KONG Prevalence CVD, including heart attack and stroke, is the third leading cause of death in Hong Kong (aft...
The Cost of Inaction: Secondary Prevention of Cardiovascular Disease in Asia-Pacific Rehabilitation ...
